Daniel Mullins

Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0.

L. Smeeth, J. Rassen, J. Gagne, 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Do Value Thresholds for Oncology Drugs Differ from Nononcology Drugs?

C. Mullins, J. Bae, Yuna H. Bae, 2014, Journal of managed care & specialty pharmacy.

Stakeholder engagement in patient-centered outcomes research: high-touch or high-tech?

Paul Wicks, C Daniel Mullins, Danielle C Lavallee, 2014, Expert review of pharmacoeconomics & outcomes research.

Treatment adherence and persistence with duloxetine, venlafaxine XR, and escitalopram among patients with major depressive disorder and chronic pain-related diseases

C. Mullins, Junling Wang, Xianchen Liu, 2011, Current medical research and opinion.

Selective cyclooxygenase-2 inhibition and cardiovascular effects: an observational study of a Medicaid population.

C. Mullins, C. Blanchette, M. Weir, 2005, Archives of internal medicine.

Recommendations for patient engagement in guideline development panels: A qualitative focus group study of guideline-naïve patients

C. Mullins, G. Gronseth, M. Armstrong, 2017, PloS one.

Do Bayesian adaptive trials offer advantages for comparative effectiveness research? Protocol for the RE-ADAPT study

Rachael Fleurence, K Jack Ishak, Jason T Connor, 2013, Clinical trials.